Drug Profile
Research programme: oncology companion diagnostics - Eli Lilly and Company/QIAGEN
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Eli Lilly and Company; QIAGEN
- Class Diagnostic agents
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer; Haematological malignancies
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Cancer(Diagnosis) in USA
- 16 Jul 2016 No recent reports of development identified for research development in Haematological-malignancies(Diagnosis) in USA
- 30 May 2014 QIAGEN and Eli Lilly and Company enter into a further collaboration agreement for companion diagnostics in Cancer